SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-20-030994
Filing Date
2020-10-13
Accepted
2020-10-13 09:16:26
Documents
59
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO 6-K ea128095-6ka_enlivextherap.htm 6-K/A 12174
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR ENLIVEX AS OF JUNE 30, ea128095ex99-1_enlivextherap.htm EX-99.1 309470
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF AND FOR THE THREE AND SIX-MON ea128095ex99-2_enlivextherap.htm EX-99.2 80725
  Complete submission text file 0001213900-20-030994.txt   3155976

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE enlv-20200630.xml EX-101.INS 640902
5 XBRL SCHEMA FILE enlv-20200630.xsd EX-101.SCH 50194
6 XBRL CALCULATION FILE enlv-20200630_cal.xml EX-101.CAL 27340
7 XBRL DEFINITION FILE enlv-20200630_def.xml EX-101.DEF 170592
8 XBRL LABEL FILE enlv-20200630_lab.xml EX-101.LAB 350974
9 XBRL PRESENTATION FILE enlv-20200630_pre.xml EX-101.PRE 183322
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-36578 | Film No.: 201234915
SIC: 2834 Pharmaceutical Preparations